To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.


Already Have an Account?

Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Vol:8 Issue:2 Number:42 ISSN#:2564-2537
ACE Report #10244
Ace Report Cover Metabolic Disorders

Romosozumab versus placebo, alendronate, and teriparatide for postmenopausal osteoporosis

How to Cite

OrthoEvidence. Romosozumab versus placebo, alendronate, and teriparatide for postmenopausal osteoporosis. ACE Report. 2019;8(2):42. Available from:

Study Type:Meta analysis
OE Level Evidence:2
Journal Level of Evidence:N/A

Romosozumab treatment in postmenopausal women with osteoporosis: a meta-analysis of randomized controlled trials

Climacteric. 2018 Apr;21(2):189-195

Contributing Authors:
B Zhang W Zhang J Wu Y Cao S Zhang Y Liu Z Li Q Tang

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


Six randomized controlled trials were included in this meta-analysis which compared the effects of romosozumab to placebo, teriparatide, and alendronate in postmenopausal osteoporosis treatment. The change in bone mineral density at the lumbar spine, total hip, and femoral neck significantly favoured romosozumab versus both placebo and active controls. Fracture rates after 24 months also significa...

Ace Report Preview Image
CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

For Reprints and Permissions, click here

Please Login or Join to leave comments.